D J McConkey
Overview
Explore the profile of D J McConkey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
2806
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Potts B, Albitar M, Anderson K, Baritaki S, Berkers C, Bonavida B, et al.
Curr Cancer Drug Targets
. 2011 Jan;
11(3):254-84.
PMID: 21247382
The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade) for...
2.
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells
Zhu K, Dunner Jr K, McConkey D
Oncogene
. 2009 Nov;
29(3):451-62.
PMID: 19881538
The ubiquitin-proteasome and lysosome-autophagy pathways are the two major intracellular protein degradation systems that work cooperatively to maintain homeostasis. Proteasome inhibitors (PIs) have clinical activity in hematological tumors, and inhibitors...
3.
Fisher M, Zhang X, McConkey D, Benedict W
Cancer Gene Ther
. 2009 Feb;
16(7):567-72.
PMID: 19197325
Adenoviral transduction of human bladder cancer cells with human interferon alpha-2b (Ad-IFN) produces cancer-specific cell death through direct and indirect mechanisms. The indirect mechanisms involve the secreted IFN produced, which...
4.
Kim K, Eton O, Davis D, Frazier M, McConkey D, Diwan A, et al.
Br J Cancer
. 2008 Aug;
99(5):734-40.
PMID: 18728664
Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of imatinib in patients with...
5.
Zhou J, Zhang X, Ashoori F, McConkey D, Knowles M, Dong L, et al.
Cancer Gene Ther
. 2008 Jul;
16(1):13-9.
PMID: 18654611
RB94, which lacks the N-terminal 112 amino-acid residues of the full-length retinoblastoma protein (RB110) is a more potent inhibitor of cancer cell growth than RB110, being cytotoxic to all cancer...
6.
Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey D, Benedict W
Cancer Gene Ther
. 2006 Nov;
14(3):241-50.
PMID: 17096027
We have previously shown that intravesical administration of adenovirus encoding human interferon alpha-2b (Ad-IFN) induced a marked regression of superficial human bladder tumors derived from cells that are resistant to...
7.
Carew J, Nawrocki S, Xu R, Dunner K, McConkey D, Wierda W, et al.
Leukemia
. 2004 Oct;
18(12):1934-40.
PMID: 15483672
B cell chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western hemisphere, yet many biological and molecular features of the disease remain undefined. CLL cells generate...
8.
Davis D, McConkey D, Abbruzzese J, Herbst R
Br J Cancer
. 2003 Jul;
89(1):8-14.
PMID: 12838293
Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis...
9.
Santamaria A, Davis D, Nghiem D, McConkey D, Ullrich S, Kapoor M, et al.
Cell Death Differ
. 2002 Apr;
9(5):549-60.
PMID: 11973613
A combination of 8-methoxypsoralen (8-MOP) and ultraviolet-A (UVA) radiation (320-400 nm) (PUVA) is widely used in the treatment of psoriasis and other skin diseases. PUVA is highly effective in eliminating...
10.
Cao X, Mohuiddin I, Ece F, McConkey D, Smythe W
Am J Respir Cell Mol Biol
. 2001 Nov;
25(5):562-8.
PMID: 11713097
It has been shown that mesothelioma expresses the antiapoptotic protein BCL-XL, but not BCL-2, rendering bcl-xl gene expression a potential therapeutic target. Sodium butyrate (NaB) is a histone deacetylase inhibitor...